Seidel C, Ziegelitz D, Frenzel R, Dittmer T
Exp Clin Endocrinol. 1984 Mar;83(1):73-86. doi: 10.1055/s-0029-1210314.
In the antithyroid drug therapy, an initial treatment with low doses (10-15 mg) of methimazole (MMI) leads to satisfactory improvement in nearly all cases and even 5 mg MMI are sufficient in more than 50% of all patients. Additional intake of thyroid hormones (Th) is not necessary, if the MMI-dosage is reduced accordingly to the individual course of treatment. Consequent follow -up is to recommend anyway, particularly under the higher MMI-doses and in the first time, respectively. Consecutive measurement of total T-3 helps in assessment of euthyroidism under treatment, whereas the response to MMI is indicated more correct by total T-4. Serial determinations of serum-TSH are very helpful to decide about the cessation of treatment. If any goitre growth occurs, it seems not to be TSH-mediated in every case. Skin reactions as side-effect of high MMI-doses can be prevented by use of low doses.
在抗甲状腺药物治疗中，初始使用低剂量（10 - 15毫克）甲巯咪唑（MMI）进行治疗，几乎在所有病例中都能带来令人满意的改善，甚至5毫克MMI对超过50%的患者就已足够。如果根据个体治疗过程相应降低MMI剂量，则无需额外摄入甲状腺激素（Th）。无论如何，都建议进行后续跟踪，尤其是在使用较高MMI剂量时以及首次治疗时。连续测量总T - 3有助于评估治疗期间的甲状腺功能正常状态，而总T - 4能更准确地表明对MMI的反应。连续测定血清促甲状腺激素（TSH）对于决定是否停止治疗非常有帮助。如果出现任何甲状腺肿大，似乎并非在每种情况下都是由TSH介导的。高剂量MMI引起的皮肤反应作为副作用，可以通过使用低剂量来预防。
